Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer.
Van Emmenis L, Ku SY, Gayvert K, Branch JR, Brady NJ, Basu S, Russell M, Cyrta J, Vosoughi A, Sailer V, Alnajar H, Dardenne E, Koumis E, Puca L, Robinson BD, Feldkamp MD, Winkis A, Majewski N, Rupnow B, Gottardis MM, Elemento O, Rubin MA, Beltran H, Rickman DS. Van Emmenis L, et al. Among authors: brady nj. Cancer Res Commun. 2023 Aug 3;3(8):1447-1459. doi: 10.1158/2767-9764.CRC-22-0491. eCollection 2023 Aug. Cancer Res Commun. 2023. PMID: 37546702 Free PMC article.
RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer.
Labrecque MP, Brown LG, Coleman IM, Lakely B, Brady NJ, Lee JK, Nguyen HM, Li D, Hanratty B, Haffner MC, Rickman DS, True LD, Lin DW, Lam HM, Alumkal JJ, Corey E, Nelson PS, Morrissey C. Labrecque MP, et al. Among authors: brady nj. Cancer Res. 2021 Sep 15;81(18):4736-4750. doi: 10.1158/0008-5472.CAN-21-0307. Epub 2021 Jul 26. Cancer Res. 2021. PMID: 34312180 Free PMC article.
N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.
Berger A, Brady NJ, Bareja R, Robinson B, Conteduca V, Augello MA, Puca L, Ahmed A, Dardenne E, Lu X, Hwang I, Bagadion AM, Sboner A, Elemento O, Paik J, Yu J, Barbieri CE, Dephoure N, Beltran H, Rickman DS. Berger A, et al. Among authors: brady nj. J Clin Invest. 2019 Jul 1;129(9):3924-3940. doi: 10.1172/JCI127961. J Clin Invest. 2019. PMID: 31260412 Free PMC article.
Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer.
Brady NJ, Bagadion AM, Singh R, Conteduca V, Van Emmenis L, Arceci E, Pakula H, Carelli R, Khani F, Bakht M, Sigouros M, Bareja R, Sboner A, Elemento O, Tagawa S, Nanus DM, Loda M, Beltran H, Robinson B, Rickman DS. Brady NJ, et al. Nat Commun. 2021 Jun 7;12(1):3372. doi: 10.1038/s41467-021-23780-y. Nat Commun. 2021. PMID: 34099734 Free PMC article.
JAK inhibition shows two faces in prostate cancer.
Brady NJ, Barbieri CE. Brady NJ, et al. Nat Cancer. 2022 Sep;3(9):1021-1023. doi: 10.1038/s43018-022-00437-3. Nat Cancer. 2022. PMID: 36138136 No abstract available.
Defining cellular population dynamics at single-cell resolution during prostate cancer progression.
Germanos AA, Arora S, Zheng Y, Goddard ET, Coleman IM, Ku AT, Wilkinson S, Song H, Brady NJ, Amezquita RA, Zager M, Long A, Yang YC, Bielas JH, Gottardo R, Rickman DS, Huang FW, Ghajar CM, Nelson PS, Sowalsky AG, Setty M, Hsieh AC. Germanos AA, et al. Among authors: brady nj. Elife. 2022 Dec 13;11:e79076. doi: 10.7554/eLife.79076. Elife. 2022. PMID: 36511483 Free PMC article.
Activation of the FGFR-STAT3 pathway in breast cancer cells induces a hyaluronan-rich microenvironment that licenses tumor formation.
Bohrer LR, Chuntova P, Bade LK, Beadnell TC, Leon RP, Brady NJ, Ryu Y, Goldberg JE, Schmechel SC, Koopmeiners JS, McCarthy JB, Schwertfeger KL. Bohrer LR, et al. Among authors: brady nj. Cancer Res. 2014 Jan 1;74(1):374-86. doi: 10.1158/0008-5472.CAN-13-2469. Epub 2013 Nov 6. Cancer Res. 2014. PMID: 24197137 Free PMC article.
Extracellular Matrix in Synthetic Hydrogel-Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors.
Mosquera MJ, Kim S, Bareja R, Fang Z, Cai S, Pan H, Asad M, Martin ML, Sigouros M, Rowdo FM, Ackermann S, Capuano J, Bernheim J, Cheung C, Doane A, Brady N, Singh R, Rickman DS, Prabhu V, Allen JE, Puca L, Coskun AF, Rubin MA, Beltran H, Mosquera JM, Elemento O, Singh A. Mosquera MJ, et al. Adv Mater. 2022 Jan;34(2):e2100096. doi: 10.1002/adma.202100096. Epub 2021 Nov 14. Adv Mater. 2022. PMID: 34676924 Free PMC article.
31 results